Dual Src/MEK blockade using saracatinib/selumetinib presents another interesting therapeutic strategy shown to induce apoptosis of dormant cancer cells and limit tumour recurrence in breast cancer models 187 that may potentially be applied to other solid cancers, including PDAC. Here, SRC is linked to cancer.